Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be ...

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.

Royalty Pharma Plc’s (NASDAQ:RPRX) portfolio includes royalties in over 35 commercial products, including Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Novartis ...

TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...